| Literature DB >> 30982526 |
Cihan Yurdaydin1, Zaigham Abbas2, Maria Buti3, Markus Cornberg4, Rafael Esteban3, Ohad Etzion5, Edward J Gane6, Robert G Gish7, Jeffrey S Glenn7, Saeed Hamid8, Theo Heller9, Christopher Koh9, Pietro Lampertico10, Yoav Lurie11, Michael Manns4, Raymundo Parana12, Mario Rizzetto13, Stephan Urban14, Heiner Wedemeyer15.
Abstract
Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.Entities:
Keywords: Hepatitis D; New treatment approaches; Surrogate marker; Treatment endpoints
Year: 2018 PMID： 30982526 DOI： 10.1016/j.jhep.2018.12.022
Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083